肿瘤标志物CEA、CA19-9和CA125在腹膜假性黏液瘤中的应用  

Value of circulating tumor markers,CEA,CA19-9,and CA125,in the management of pseudomyxoma peritonei

作　　者：黄永红[1] 唐鸿生[1] 阮强[1] 张相良[1] 王进[1] 

机构地区：[1]广州医科大学附属肿瘤医院,广东广州510095

出　　处：《结直肠肛门外科》2016年第5期458-460,共3页Journal of Colorectal & Anal Surgery

基　　金：广州医科大学校级项目(编号:2015C36)

摘　　要：目的探讨肿瘤标志物CEA、CA19-9和CA125在腹膜假性黏液瘤(PMP)中的应用价值。方法收集在本院进行规范化肿瘤细胞减灭术(CRS)+腹腔热灌注化疗(HIPEC)的47例PMP患者临床资料,分析肿瘤标志物CEA、CA19-9和CA125水平在术前、术后的变化,与细胞减灭评分(CCR)以及复发时间的关系。结果 47例患者术前CEA、CA19-9和CA125的阳性率分别为83%、60%和68%,经过规范化CRS+HIPEC治疗均有不同程度的下降,差异有统计学意义(P<0.05);CA19-9阴性者更容易进行充分的手术减瘤,而且其中位复发时间(15个月)明显优于CA19-9阳性组(9个月)(P<0.05)。结论肿瘤标志物CA19-9可作为PMP病情估计、预后评价的重要参考指标。Objective To evaluate the clinical value of circulating tumor markers CEA, CA19-9, and CA125 in the management of pseudomyxoma peritonei （PMP）. Methods We conducted retrospective analysis of clinical data of 47 PMP patients who received the standardized cytoreduction surgery （CRS） and hyperthermieintraperitoneal chemotherapy （HIPEC） in our hospital. Levels of CEA, CA19-9, and CA125 were assessed pre-operatively and post-operatively. Correlations between levels of these markers and complete- ness of cytoreduction （CCR） and relapse time were analyzed. Results At baseline, diagnostic sensitivity was 83% for CEA, 60% for CA19-9, and 68% for CA125. After CRS＋HIPEC, all the circulating tumor markers, CEA, CA19-9, and CA125, were reduced signifi- cantly. Compared with those who had elevated pre-operative CA19-9 level, patients who had normal pre-operative CA19-9 level were more likely to achieve adequate CRS and had delayed time in relapse （15 months vs. 9 months, P〈0.05）. Conclusion Circulating tu- mor markers CA19-9 could be considered as an important marker in disease progression and prognosis for PMP.

关 键 词：腹膜假性黏液瘤 CEA CA19-9 CA125 

分 类 号：R735.5[医药卫生—肿瘤]